The National Lung Screening Trial (NSLT) showed a 20% reduction in death from lung cancer, but with a number needed to screen of 320 to prevent one death, a false-positive rate of 96% and each abnormal scan generating costs of ~$45,000, the risk / benefit / cost accounts are far from settled.